C9orf16

Across TCGA pan-cancer cohorts, C9orf16 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of C9orf16’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where C9orf16 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types C9orf16 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

THCA, COAD, and LIHC are the cancer types where C9orf16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C9orf16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	+1.607	<.001	11	view →
COAD	Female	II,III,IV	+1.359	<.001	11	view →
LIHC	All	II,III,IV	+1.535	<.001	9	view →
KIRP	Male	III,IV	+1.152	<.001	8	view →
STAD	Male	II,III,IV	+1.014	<.001	6	view →
UCEC	All	All	+0.889	<.001	6	view →
LUSC	Female	All	+0.756	<.001	6	view →
BRCA	Female	All	+0.308	<.001	6	view →
KIRC	All	II,III,IV	−0.464	.004	5	view →
CHOL	Male	All	+1.808	<.001	3	view →
READ	All	All	+1.411	<.001	3	view →
LUAD	Female	III,IV	+0.647	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

C9orf16–THCA

Open the THCA breakdown →